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Abstract
Background: Vitamin D has a potential role in slowing HIV disease progression and preventing mortality based on its
extensive involvement in the immune system; however, this relationship has not been examined in large studies or in
resource-limited settings.
Methodology/Principal Findings: Vitamin D levels were assessed in 884 HIV-infected pregnant women at enrollment in a
trial of multivitamin supplementation (not including vitamin D) in Tanzania. Women were followed up for a median of 69.5
months, and information on hemoglobin levels, HIV disease progression, and mortality was recorded. Proportional hazard
models and generalized estimating equations were used to assess the relationship of these outcomes with vitamin D status.
Conclusions/Significance: Low vitamin D status (serum 25-hydroxyvitamin D,32ng/mL) was significantly associated with
progression to WHO HIV disease stage III or greater in multivariate models (incidence rate ratio [RR]: 1.25; 95% confidence
intervals [CI]: 1.05, 1.50). No significant relationship was observed between vitamin D status and T-cell counts during follow-
up. Women with low vitamin D status had 46% higher risk of developing severe anemia during follow-up, compared to
women with adequate vitamin D levels (RR: 1.46; 95% CI: 1.09, 1.96). Women in the highest vitamin D quintile had a 42%
lower risk of all-cause mortality, compared to the lowest quintile (RR: 0.58; 95% CI: 0.40, 0.84). Vitamin D status had a
protective association with HIV disease progression, all-cause mortality, and development of anemia during follow-up in
HIV-infected women. If confirmed in randomized trials, vitamin D supplementation could represent a simple and
inexpensive method to prolonging the time to initiation of antiretroviral therapy in HIV-infected patients, particularly in
resource-limited settings.
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Introduction
Human Immunodeficiency Virus (HIV) disease is characterized
by a progressive deterioration in immune function. Interventions
that offset this impairment have the potential to slow HIV disease
progression and improve quality of life. The latter has become
increasingly important in the face of HIV infection becoming a
chronic disease in those with access to anti-retroviral therapy
(ART).
Vitamin D may represent one such intervention with its
extensive involvement in the human immune response. Vitamin
D has several important metabolic functions, including regulation
of calcium movement in gastrointestinal mucosa, renal tubules,
and the skeleton [1]. An increase in the occurrence of infections in
children with rickets, the classic vitamin D deficiency disease has
been reported, although the mechanisms implicated are not fully
understood [2]. Laboratory studies have suggested an important
role of vitamin D in immune regulation; the discovery of vitamin
D receptors (VDRs) on peripheral blood mononuclear cells has
fuelled the interest in vitamin D as an immune modulator [3].
More recently, vitamin D has been shown to have an integral role
in innate immunity and response to infections such as tuberculosis
[4,5,6].
Few studies have examined the relationship of vitamin D with
HIV disease progression or survival [7]; one small longitudinal
study in Norway found that HIV-infected patients with low 1,25-
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metabolite of vitamin D, had significantly shorter survival time
than those with normal concentrations [8]. The Trial of Vitamins
[9] conducted in Tanzania, in which HIV-infected pregnant
women were supplemented with multivitamins (not including
vitamin D) and followed up to observe pregnancy outcomes and
disease progression, provides an opportunity to expand our
knowledge on vitamin D status and health, with particular
relevance to HIV infection.
Methods
Ethics Statement
Verbal informed consent was obtained from all participants due
to the low rates of literacy in Tanzania and the procedure is
detailed in an earlier publication [10]. The study protocol was
approved by the Research and Publications Committee of the
Muhimbili University College of Health Sciences, the Ethical
Committee of the National AIDS Control Program of the
Tanzanian Ministry of Health, and the Institutional Review
Board of the Harvard School of Public Health.
Study Population
The study design has been previously described in detail [10].
Briefly, participants were HIV-infected pregnant women enrolled
in a randomized, double-blind, placebo-controlled trial of vitamin
supplementation (1995–1997). Pregnant women (12–27 weeks
gestation) were randomized to receive one of four regimens from
enrollment until at least 18 months after delivery: i) vitamin A
alone (30mg b-carotene, 5000 IU preformed vitamin A); ii)
multivitamins including vitamin A (30mg b-carotene, 5000 IU
preformed vitamin A, 20mg B1, 20mg B2, 100mg B3, 25mg B6,
50mgB 12, 500mg C, 30mg E, 0.8mg folic acid); iii) multivitamins
excluding vitamin A; or placebo. At delivery, women in vitamin A
groups were given an additional oral dose of vitamin A
(200,000 IU), whereas women in the other two groups received
a placebo. All women received iron-folate daily and chloroquine
weekly as malaria prophylaxis, according to national guidelines for
antenatal care at the time the trial was conducted. At the time of
the study, ART was not available to most women in Tanzania,
including participants in the trial.
Assessment of Baseline Covariates
Structured interviews were conducted during the baseline visit
to collect information on demographic characteristics including
age, educational level, and money spent on food per day. Data
were also collected on morbidities, symptoms, and hospitalizations
during the current pregnancy. Study physicians conducted a
complete medical examination and collected blood, urine, stool,
and vaginal swab specimens. HIV disease stage was classified in
accordance with the World Health Organization (WHO)
guidelines [11]. Anthropometric measurements were obtained by
trained research assistants using standardized procedures and
calibrated instruments.
Assessment of Outcomes
Women were followed through monthly study clinic visits,
where physicians performed a clinical examination, and a nurse
assessed self-reported symptoms and HIV-related complications in
the preceding period. HIV disease stage was assessed at each visit,
in accordance with WHO criteria [11]. Women who missed a
clinic visit or travelled out of Dar es Salaam were followed via a
home visit and neighbors or relatives were asked about vital status.
Verbal-autopsy techniques were used to ascertain the cause of
death, by conducting standardized interviews with relatives and
reviewing medical records.
Laboratory Methods
Blood samples were obtained from study participants at
enrollment (12–27 weeks of gestation), and plasma was stored at
or below 270uC. Maternal vitamin D status was assessed using
serum levels of 25-hydroxyvitamin D [25(OH)D]. Serum
25(OH)D levels were measured by the fully automated chemilu-
minescence ADVANTAGE 25(OH)D assay system obtained from
Nicholas Institute Diagnostics, San Juan Capistrano, CA. Absolute
CD4, CD8, and CD3 T-cell counts were evaluated with the
FACSCount system (Becton-Dickinson, San Jose, CA). Hemoglo-
bin levels were assessed using either a CBC5 Coulter Counter
(Coulter Corporation, Miami) or by the cyanmethemoglobin
method with use of a colorimeter (Corning Inc, Corning, NY).
HIV-1 serostatus was determined by the Enzygnost anti-HIV-1/2
Plus assay (Dade Behring, Germany) followed by the Wellcozyme
HIV-1 recombinant test (Murex Biotech Ltd, Dartford, UK).
Discordant results were resolved using Western blot test (Bio-Rad
Laboratories Ltd., Hertfordshire, UK) [12].
Sera and genital swabs were collected to test for candidiasis and
sexually transmitted infections (STIs) including syphilis, gonor-
rhea, and trichomoniasis. Malaria parasites were identified in
thick-smear blood films stained with giemsa. Stool specimens were
examined by Kato Katz concentration technique to identify
intestinal helminthic and pathogenic protozoan infections. STIs,
malaria, and intestinal parasitic infections were treated at the time
of diagnosis according to the Tanzanian Ministry of Health
standards for prenatal care.
A blood specimen was collected every six months after
randomization for measurement of hemoglobin and T-cell subsets.
Thin blood films with Leishman’s stain were prepared and
examined microscopically. Hypochromasia was classified into 4
levels, coded as absent, 1+,2 +, and 3+. Persons who were
diagnosed with severe anemia received management according to
standard of care, including treatment for parasitic infections, iron
supplementation if indicated, and dietary counseling.
Statistical Analyses
We examined the relationship of vitamin D status at baseline
with mortality, HIV disease progression, and anemia using
proportional hazards models [13]. Vitamin D status was defined
in two ways: insufficient (,32ng/mL or ,80nmol/L) vs. adequate
and in quintiles based on the distribution of vitamin D levels in this
population. The cut-off of 32ng/mL for vitamin D insufficiency
was based on requirements for optimal calcium homeostasis [14]
and previous studies [15]. We examined the times to: death from
AIDS-related causes, all-cause death, progression to WHO stage
III or higher, and composite endpoints of mortality and HIV
disease progression. For those without the outcomes, follow-up
ended on the date on which the stage was last assessed.
The relationship of vitamin D status with T-cell counts was
analyzed with generalized estimating equations and SAS Proc
Genmod software. Change in T-cell counts between consecutive
visits was modeled as a continuous response variable with vitamin
D status and other covariates as explanatory variables across the
repeated measures in each individual. Robust estimators of the
variance were used to construct confidence intervals, using a
working correlation matrix with m-dependent structure and m=1
(assumes correlations between adjacent observations are non-zero
and equal). We also examined potential non-linear relationships of
change in T-cell counts between consecutive visits with time since
randomization non-parametrically with restricted cubic splines
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selected cubic spline terms to the above-specified model as
covariates with vitamin D status.
We used proportional hazard models to investigate the
relationship of vitamin D status with time to the first occurrence
of each definition of anemia. Women who had the endpoint of
interest at baseline were excluded. Anemia was defined as
hemoglobin ,110g/L, and severe anemia as hemoglobin ,85g/
L. We examined the morphology of peripheral red blood cells as a
proxy for iron deficiency (hypochromic microcytic cells) and
vitamin B-12 and folate deficiency (macrocytic cells) [18].
Hypochromic microcytic anemia was categorized as severe
(hypochromasia$2, microcytosis), moderate and above (hypo-
chromasia$1, microcytosis), and mild and above (hypochroma-
sia$1, with or without microcytosis). Macrocytosis was defined as
the presence of any macrocytic cells.
We investigated potential non-linear relationship of continuous
vitamin D levels with the risk of major outcomes, including HIV
disease progression and mortality non-parametrically with step-
wise restricted cubic splines [16,17]. Tests for non-linearity used
the likelihood ratio test, comparing the model with only the linear
term to the model with the linear and the cubic spline term.
We adjusted for possible confounders of baseline vitamin D
levels and age, WHO HIV disease stage and CD4 T-cell count at
baseline, and treatment regimen as a priori risk factors for the
outcomes in all multivariate models, except for change in T-cell
counts. This strategy to control confounding uses prior knowledge
to identify potential confounders, and includes those that lead to a
greater than 10% ‘change-in-estimate’ for the incidence rate ratio
of vitamin D status in the model [19]. Baseline T-cell counts were
not adjusted for in the multivariate model for change in T-cell
counts, since, in analysis of covariance models, it gives biased
estimates in non-randomized studies. Observations with missing
data for covariates were retained in the analysis using the missing
indicator method for variables missing greater than 1% of the
observations [20]. Statistical analyses were performed using SAS
software version 9.2 (SAS Institute Inc., Cary, NC, US).
Results
Of the 1078 women enrolled in the trial, baseline vitamin D
concentrations were known for 885; one woman was excluded for
having WHO HIV stage IV disease. The median follow-up time
for participants included in this analysis was 69.5 months
(Interquartile Range: 44.7–79.3 months). Baseline characteristics
of the 884 women included in this analysis are presented in
Table 1. T-cell counts measured at least twice during follow-up
were available for only 636 women. There was no significant
difference in CD4 T-cell counts at baseline between the women
with low vitamin D and women with adequate vitamin D
(Wilcoxon test; p=0.29). However, CD8 and CD3 T-cell counts
were significantly higher in women with low vitamin D, compared
to women with adequate vitamin D (p,0.01, p=0.02, respec-
tively). The results obtained in analyses with low vs. adequate
Table 1. Baseline Characteristics of Women enrolled in the
trial with available vitamin D levels (N=884).
Low Vitamin D
(n=347)
Adequate
Vitamin D
(n=537)
Variable
Mean 6 SD* or
Frequency (%)
Mean 6 SD or
Frequency (%)
Age
Less than 20 years 45 (12.97) 71 (13.22)
20–24 years 144 (41.50) 213 (39.66)
25–29 years 105 (30.26) 166 (30.91)
Greater than or equal to 30 years 53 (15.27) 87 (16.20)
WHO HIV Stage
I 278 (80.12) 457 (85.10)
II 60 (17.29) 75 (13.97)
III 9 (2.59) 5 (0.93)
CD4 Category, cells/mL
1( ,200) 46 (13.94) 61 (12.01)
2 (200 to 500) 185 (56.06) 280 (55.12)
3( .=500) 99 (30.00) 167 (32.87)
CD3, cells/mL 1282.986456.36 1209.556457.99
CD8, cells/mL 808.686354.06 722.036317.82
Hemoglobin at baseline, g/L 93.50617.29 95.25616.70
Vitamin D [Serum 25(OH)D] at
baseline, ng/mL
24.2266.16 43.0769.40
*SD: Standard Deviation.
doi:10.1371/journal.pone.0008770.t001
Table 2. Vitamin D Status and HIV Disease Progression and Mortality among HIV-infected Women.
Vitamin D
Low Adequate Univariate Models Multivariate Models
1
Outcome % (N)
2 %( N )
2 RR (95% CI) P
3 RR (95% CI) P
3
Progression to $ HIV disease stage III 60.1 (333) 61.2 (531) 1.20 (1.00, 1.43) 0.05 1.25 (1.05, 1.50) 0.01
Progression to $ HIV disease stage III or death
from AIDS-related causes
67.8 (338) 66.4 (533) 1.20 (1.02, 1.42) 0.03 1.26 (1.06, 1.49) 0.01
Progression to $ HIV disease stage III or death
from all causes
71.7 (339) 71.7 (533) 1.19 (1.01, 1.40) 0.04 1.23 (1.04, 1.45) 0.01
Death from AIDS-related causes 22.5 (347) 22.9 (537) 1.04 (0.78, 1.38) 0.79 1.11 (0.83, 1.48) 0.47
Death from all causes 32.9 (347) 32.2 (537) 1.08 (0.85, 1.37) 0.51 1.13 (0.89, 1.43) 0.34
1All multivariate models adjusted for age, treatment regimen, CD4 T-cell counts at baseline, and HIV disease stage at baseline.
2% (N): Percentage of cases (Total number).
3p-values obtained from Cox regression models.
doi:10.1371/journal.pone.0008770.t002
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quintiles (data not shown), unless noted below.
During follow-up, 287 women died: 201 of AIDS-related causes.
525 women progressed to WHO HIV stage III disease or higher
(Table 2). After multivariate adjustment, the risk of progression to
stage III disease or greater was 1.25 times greater in women with
low baseline vitamin D concentrations (95% CI: 1.05, 1.50;
p=0.01), compared to women with adequate vitamin D status. In
additional analyses, the relationship between continuous vitamin
D levels and risk of disease progression was linear with the risk of
disease progression decreasing with increasing vitamin D levels
(p=0.05; Figure 1).
There was no relationship observed with either death from
AIDS-related causes or death from all causes with the binary
variable of low versus adequate vitamin D. However, the women
in the highest vitamin D quintile had a 42% lower risk of all-cause
mortality compared to women in the lowest quintile (Incidence
Rate Ratio [RR]: 0.58; 95% CI: 0.40, 0.84; p,0.01). In analyses
with continuous vitamin D levels as the exposure, a significant
linear relationship was observed with all-cause mortality; the risk
of all-cause mortality declined with increase in vitamin D levels
(p,0.01; Figure 2).
Although women in the low vitamin D group had significantly
higher CD8 and CD3 T-cell counts at baseline, there was no
evidence that vitamin D status influenced any further change in
CD4, CD8, and CD3 T-cell counts during follow-up (Table 3).
A significant association was also observed between low vitamin
D status and anemia and markers of iron deficiency (Table 4).
Women with low vitamin D levels at baseline had a 46% higher
risk (RR: 1.46; 95% CI: 1.09, 1.96; p=0.01) of developing severe
anemia during follow-up in multivariate models, compared to
women with adequate vitamin D levels. The rate ratio for severe
Figure 1. Relationship of Vitamin D status with progression to HIV disease stage III or IV during follow-up.
doi:10.1371/journal.pone.0008770.g001
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doi:10.1371/journal.pone.0008770.g002
Table 3. Vitamin D Status and T-cell Subset Counts in HIV-infected Women (n=636).
Estimated 6 month change in T-cell counts (95% CI)
Time-adjusted models
1 Multivariate adjusted models
2
End point Low Vitamin D Adequate Vitamin D P Low Vitamin D Adequate Vitamin D P
CD4, cells/mL 270.24 (299.08, 241.41) 269.12 (297.45, 240.80) 0.65 275.01 (2104.21, 245.81) 274.43 (2102.82, 246.05) 0.82
CD8, cells/mL 2172.65 (2265.60, 279.69) 2168.18 (2259.90, 276.45) 0.39 2170.48 (2263.50, 277.45) 2166.58 (2258.54, 274.63) 0.46
CD3, cells/mL 2233.07 (2329.03, 2137.10) 2227.25 (2322.88, 2131.63) 0.39 2240.05 (2335.77, 2144.34) 2235.38 (2330.37, 2140.40) 0.49
1Time-adjusted models adjusted for length of interval between two successive measurements and time since randomization.
2All multivariate models adjusted for age, treatment regimen, and HIV disease stage at baseline.
doi:10.1371/journal.pone.0008770.t003
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baseline was 2.56 (95% CI: 1.72, 3.79; p,0.01). No significant
relationship of vitamin D status was observed with macrocytosis.
Discussion
In this study, low vitamin D levels at baseline were significantly
associated with increased risk of HIV disease progression, severe
anemia, and hypochromic microcytosis in HIV-infected Tanza-
nian women. Women in the highest quintile of vitamin D also had
a significantly lower risk of all-cause mortality compared to women
in the lowest quintile of vitamin D. In contrast, no significant
association of vitamin D status was observed with AIDS-related
mortality or T-cell counts.
There is a paucity of research on the relationship of vitamin D
with HIV-related health outcomes, particularly in resource-limited
settings. Most of the published studies are cross-sectional
comparisons of vitamin D levels in HIV-infected patients
compared to HIV-uninfected controls. For example, a small study
in Switzerland found no significant difference between 25(OH)D
concentrations in 6 patients with advanced AIDS, compared to 10
HIV-uninfected controls [21]. In a study from Germany,
1,25(OH)2D and 25(OH)D levels were both significantly lower
among men and women with HIV-infection (asymptomatic, on
ART), compared to uninfected controls [22]. In a study in
Norway, mean serum 1,25(OH)2D concentrations were signifi-
cantly lower in HIV-infected patients, compared to healthy,
seronegative blood donors; 1,25(OH)2D levels were lowest in
symptomatic patients, independent of the presence of opportunis-
tic infections [8].
One small longitudinal study in Norway (n=53) assessed the
association between vitamin D levels and survival among HIV-
infected individuals. Patients with 1,25(OH)2D levels below 25ng/
L at baseline had a shorter survival time than those with normal
concentrations, after adjusting for CD4 T-cell counts. The
association appeared to be stronger in individuals with CD4
counts less than 50/mL [8].
The protective association of vitamin D against HIV disease
progression may be explained by its role in immune function.
Vitamin D has been shown to improve phagocytic capacity of
macrophages, cell-mediated immunity, and increase natural killer
cell number and cytolytic activity, suggesting an important role in
response to infections. Laboratory studies have identified several
mechanisms by which vitamin D could slow HIV disease
progression [7]. For example, 1,25(OH)2D decreases CD4 surface
receptor expression in promyelocytic leukemia cell line [23] and
human monocytes [24]. If confirmed, these results could constitute
a mechanism to control viral entry and cytopathogenic effects. In
another study, in vitro pre-treatment of human peripheral blood
monocytes with 1,25(OH)2D, but not 25(OH)D, decreased HIV
infection by 95% [25]. The recent elucidation of vitamin D’s role
in the innate immune response via toll-like receptors (TLRs) [4],
suggests potential modulation of pathogen entry by vitamin D and
its metabolites. This mechanism has been shown to be important
in the immune system’s response to tuberculosis; TLR stimulation
of human macrophages up-regulates the expression of VDRs and
induces the enzyme (CYP27b1) that catalyzes the conversion of
25(OH)D to 1,25(OH)2D, the biologically active metabolite of
vitamin D. In presence of adequate 25(OH)D, VDR upregulation
leads to cathelicidin induction, an antimicrobial peptide with
direct action against intracellular pathogens including Mycobacte-
rium tuberculosis [4], a leading cause of disease progression and
mortality among HIV-infected patients [26]. Increased resistance
to tuberculosis could potentially prolong survival in these patients.
Our study did not find any relationship of vitamin D with
change in T-cell counts during follow-up. Though there are
several laboratory studies linking vitamin D with T-cell function,
no studies have found such an association in vivo in HIV-infected
patients. It is possible that beneficial effects of vitamin D may be
via modulation of innate immunity, rather than cell-mediated
immunity.
Our finding of a relationship between vitamin D status and risk
of severe anemia and iron deficiency could have several potential
explanations. Iron deficiency impairs intestinal fat absorption, and
may consequently decrease vitamin D absorption [27]. Converse-
ly, vitamin D deficiency could cause anemia via increased
inflammation or marrow myelofibrosis [28]. An association
between low vitamin D status and lower hemoglobin levels or
iron deficiency has been observed in earlier studies in individuals
with renal disease in NHANES III [29] and in studies in children
in minority communities in Britain. For example, in a study in 145
Asian children in Birmingham, the children with low plasma
Table 4. Vitamin D Status and Hematological Outcomes.
Vitamin D
Low Adequate Univariate models Multivariate models
6
Outcome % (N)
2 %( N )
2 HR (95% CI) P
1 HR (95% CI) P
1
Severe Anemia (Hb ,85g/L) 38.7 (212) 31.0 (339) 1.44 (1.08, 1.92) 0.01 1.46 (1.09, 1.96) 0.01
Anemia (Hb ,110g/L) 92.5 (40) 83.0 (94) 1.18 (0.80, 1.75) 0.40 1.19 (0.77, 1.83) 0.43
Hypochromic microcytosis
Severe
3 21.9 (256) 10.5 (391) 2.34 (1.58, 3.45) ,0.01 2.56 (1.72, 3.79) ,0.01
Moderate and above
4 43.6 (234) 34.8 (399) 1.39 (1.08, 1.80) 0.01 1.45 (1.12, 1.88) 0.01
Mild and above
5 73.5 (151) 66.3 (261) 1.39 (1.10, 1.77) 0.01 1.41 (1.10, 1.80) 0.01
Macrocytosis 4.5 (269) 4.8 (439) 0.99 (0.49, 2.02) 0.99 1.11 (0.54, 2.28) 0.77
1p-values are from Cox Regression Models.
2% (N): Percentage of cases (Total number).
3Severe: Hypochromasia $2+ and microcytic cells observed.
4Moderate and above: Hypochromasia $1+ and microcytic cells observed.
5Mild and above: Hypochromasia $1+.
6All multivariate models adjusted for age, CD4 T-cell counts, HIV disease stage at baseline, and regime received.
doi:10.1371/journal.pone.0008770.t004
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serum iron concentrations [30]. In Bangladeshi, Pakistani, and
Indian communities in England, one-fifth of children surveyed
showed signs of both deficiencies; during the winter 50% of
children with low vitamin D had low hemoglobin levels (vs. 0% in
children with normal vitamin D). Iron deficiency was a significant
risk factor for low vitamin D levels in all three ethnic groups [31].
A limitation of the current analysis is the possibility of reverse
causation; since vitamin D levels were assessed at baseline when
participants were already HIV-infected, the temporal relationship
between HIV and vitamin D status could not be ascertained. It is
possible that advanced HIV disease may lead to lower serum
25(OH)D levels. However, most participants were stage I disease
at baseline. Additionally, controlling for baseline CD4 T-cell
counts and HIV disease stage strengthened the observed
associations, weakening the possibility of reverse causation.
Another limitation is that the assay for vitamin D assessment does
not measure vitamin D2, the form of vitamin D obtained through
supplements, reliably; however supplementation was unlikely in this
population. Additionally, our choice of cut-off for vitamin D is to
make results clinically more relevant and comparable with other
studies; however, similar effect estimates were obtained for major
outcomes such as HIV disease progression and anemia by using
population-based quintiles of vitamin D. Further, potential
modification of vitamin D status by ART could not be examined,
as study participants were not receiving ART.
Our study provides initial support for a potentially beneficial effect
of adequate vitamin D status on HIV diseaseand related outcomes. If
confirmed in randomized controlled trials, vitamin D supplementa-
tion could be a simple and low cost method to prolong the time to
initiation of anti-retroviral therapy in HIV-infected patients,
particularly in resource-limited settings. Evidence from larger studies
and randomized trials is urgently needed to examine the effects of
vitamin D in HIV-infected patients and its interaction with ART.
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